EarliPoint Health Launches Skill Illustrator™ to Help Providers Translate Assessment Data into Actionable Developmental Insights.

Read Release →

The Right Dose: Treatment Intensity, Evidence, and Earning Payer Trust in ABA

In this episode of the EarliPoint Exchange, hosts Dr. Cheryl Tierney and Kirsten Yurich, BCBA, sit down with Dr. Gina Green, PhD, BCBA-D — a legendary behavior analyst whose career spans basic research, applied assessment and intervention, and decades of leadership in the profession and its standards.

The conversation traces the empirical roots of comprehensive, intensive ABA intervention for young children autism: where the widely cited recommendation of roughly 40 hours per week originated, what the best available scientific evidence does and does not tell us about the intensity of comprehensive and focused ABA interventions, and professional standards for individualizing intensity and all other aspects of ABA interventions to the circumstances of each client and their family. From there, the discussion turns to the realities of delivering ABA interventions in today’s environment of funding and workforce pressures and some strategies agencies can use to see that each client receives the level and quality of intervention that is most likely to maximize improvements.

Finally, Dr. Green explores the growing payer emphasis on client outcomes and audits of billing claims. She offers suggestions for agencies to build credibility with funders by using well-researched, valid, reliable outcome measures and sound documentation practices while also advocating for payer policies that support high-quality, data-based care. This session emphasizes behavior-analytic decision-making and measurement throughout, connecting scientific evidence to the accountability the current funding environment demands.

The webinar will be held on September 22, 2026, from 12PM-1PM, and includes 1 BACB® GEN CEU. Attendance is included free with a BehaviorLive subscription, and registrants will also have access to the recorded session on-demand for CEUs.

Learning Objectives

  • Describe the history of comprehensive, intensive ABA intervention for young children with autism, including the origin of the 40-hour-per-week recommendation. Summarize the current scientific evidence on the relation between ABA treatment intensity and outcomes for young children with autism.
  • Identify variables that should inform individualized recommendations regarding intensity and other aspects of ABA interventions according to the profession’s standards of care.
  • Discuss strategies agencies can use to support delivery of ABA interventions that are consistent with the best available scientific evidence and professional standards under current funding and staffing constraints.

Pete Polgar

VP of Marketing

Pete Polgar is the Vice President of Marketing at Earlipoint. He leads the company’s marketing strategy, focusing on brand positioning, demand generation, and digital growth. With a background in performance marketing and content strategy, Pete works on aligning marketing initiatives with business development to drive measurable results and expand Earlipoint’s market presence.

Latest News

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder